FR3140243A1 - Dietary supplement - Google Patents
Dietary supplement Download PDFInfo
- Publication number
- FR3140243A1 FR3140243A1 FR2209995A FR2209995A FR3140243A1 FR 3140243 A1 FR3140243 A1 FR 3140243A1 FR 2209995 A FR2209995 A FR 2209995A FR 2209995 A FR2209995 A FR 2209995A FR 3140243 A1 FR3140243 A1 FR 3140243A1
- Authority
- FR
- France
- Prior art keywords
- vitamin
- food supplement
- supplement according
- food
- caffeine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 31
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 14
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 11
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 10
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960002477 riboflavin Drugs 0.000 claims abstract description 8
- 229960003495 thiamine Drugs 0.000 claims abstract description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 7
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960001948 caffeine Drugs 0.000 claims abstract description 7
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000011777 magnesium Substances 0.000 claims abstract description 7
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 7
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims abstract description 6
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 claims abstract description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims abstract description 6
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000011701 zinc Substances 0.000 claims abstract description 6
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 6
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims abstract description 5
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 claims abstract description 5
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 claims abstract description 5
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 claims abstract description 5
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 claims abstract description 5
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 claims abstract description 5
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 5
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 5
- 229930003571 Vitamin B5 Natural products 0.000 claims abstract description 5
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims abstract description 5
- 229960002079 calcium pantothenate Drugs 0.000 claims abstract description 5
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 5
- 239000000419 plant extract Substances 0.000 claims abstract description 5
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000013589 supplement Substances 0.000 claims abstract description 5
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 5
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 5
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 5
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 5
- 235000009492 vitamin B5 Nutrition 0.000 claims abstract description 5
- 239000011675 vitamin B5 Substances 0.000 claims abstract description 5
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 5
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 5
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 5
- 229930013930 alkaloid Natural products 0.000 claims abstract description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 4
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 4
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims abstract description 3
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims abstract description 3
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 claims abstract description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000002253 acid Substances 0.000 claims abstract description 3
- 235000013305 food Nutrition 0.000 claims abstract description 3
- 235000019192 riboflavin Nutrition 0.000 claims abstract description 3
- 239000002151 riboflavin Substances 0.000 claims abstract description 3
- 235000019157 thiamine Nutrition 0.000 claims abstract description 3
- 239000011721 thiamine Substances 0.000 claims abstract description 3
- 235000019160 vitamin B3 Nutrition 0.000 claims abstract description 3
- 239000011708 vitamin B3 Substances 0.000 claims abstract description 3
- 108010044467 Isoenzymes Proteins 0.000 claims abstract 2
- 230000001939 inductive effect Effects 0.000 claims abstract 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000011669 selenium Substances 0.000 claims description 4
- 229910052711 selenium Inorganic materials 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229940112822 chewing gum Drugs 0.000 claims description 2
- 235000015218 chewing gum Nutrition 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 238000004040 coloring Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 235000020686 ginkgo biloba extract Nutrition 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims 1
- 239000008393 encapsulating agent Substances 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000011477 surgical intervention Methods 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 208000015380 nutritional deficiency disease Diseases 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000007124 immune defense Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000007391 self-medication Methods 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitrogen oxide(NO) Natural products O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000126014 Valeriana officinalis Species 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 235000013928 guanylic acid Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 201000006385 lung benign neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000016788 valerian Nutrition 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Complément alimentaire comprenant de la vitamine B1 (thiamine), de la vitamine B2 (riboflavine), de la vitamine B5 (acide panthoténique), de la vitamine B6, de la vitamine C (acide ascorbique), du zinc et du magnésium, ledit complément alimentaire étant essentiellement exempt des vitamines B3, B8, B9, B12, A, D, E et K, de polyphénols, d’alcaloïdes différents de la caféine, et de tout extrait végétal susceptible d’inhiber ou induire l’un quelconque des isoenzymes CYP1A2, CYP2C9, CYP2D6 et CYP3A4 du cytochrome P450 ou d’interagir avec l’agrégation plaquettaire, et utilisations.Food supplement comprising vitamin B1 (thiamine), vitamin B2 (riboflavin), vitamin B5 (panthotenic acid), vitamin B6, vitamin C (ascorbic acid), zinc and magnesium, said supplement food being essentially free of vitamins B3, B8, B9, B12, A, D, E and K, polyphenols, alkaloids other than caffeine, and any plant extract capable of inhibiting or inducing any of the isoenzymes CYP1A2, CYP2C9, CYP2D6 and CYP3A4 of cytochrome P450 or interact with platelet aggregation, and uses.
Description
La présente invention concerne un complément alimentaire destiné à une utilisation en péri-opératoire, à savoir antérieurement ou postérieurement à une intervention chirurgicale.The present invention relates to a food supplement intended for perioperative use, namely before or after a surgical procedure.
Un complément alimentaire contient des nutriments, en particulier vitamines, sels minéraux, oligoéléments, ainsi que toute autre substance ayant un effet nutritionnel ou physiologique, d’origine naturelle ou de synthèse, telle que des acides gras, des acides aminés, des protéines, des extraits végétaux, et a pour but de pallier les insuffisances d’un régime alimentaire normal causées par des circonstances particulières telles qu’une suractivité, une grossesse, une période de stress, la croissance, le vieillissement…, d’un régime alimentaire particulier susceptible d’entraîner des carences tel que celui des végétariens et des végétaliens, ou même d’un régime alimentaire normal en vue de diminuer les facteurs de risques de maladies. Les ingrédients d’un complément alimentaire et leurs teneurs sont choisis en fonction de l’indication recherchée.A food supplement contains nutrients, in particular vitamins, mineral salts, trace elements, as well as any other substance having a nutritional or physiological effect, of natural or synthetic origin, such as fatty acids, amino acids, proteins, plant extracts, and aims to compensate for the insufficiencies of a normal diet caused by particular circumstances such as overactivity, pregnancy, a period of stress, growth, aging, etc., of a particular diet susceptible cause deficiencies such as that of vegetarians and vegans, or even a normal diet in order to reduce disease risk factors. The ingredients of a food supplement and their contents are chosen according to the desired indication.
Des compléments alimentaires ou DADFMS (Denrées Alimentaires Destinées à des Fins Médicales Spéciales) sont ainsi utilisés dans des situations pré- ou post-opératoires dans lesquelles ils ont généralement vocation à rétablir à la normale le statut d’un patient dénutri. Ils sont habituellement prescrits par un médecin (chirurgien, anesthésiste) et sont hyperprotidiques. La dénutrition post-opératoire provoque en effet une diminution des défenses immunitaires, des fonctions musculaires… et constitue un facteur important de risque de mortalité. Ils contribuent aussi à réduire les complications post-opératoires comme les infections, les retards de cicatrisation, avec des principes actifs appropriés.Food supplements or DADFMS (Foods Intended for Special Medical Purposes) are thus used in pre- or post-operative situations in which they are generally intended to restore the status of a malnourished patient to normal. They are usually prescribed by a doctor (surgeon, anesthesiologist) and are high in protein. Post-operative malnutrition causes a reduction in immune defenses and muscle functions, etc. and constitutes a significant risk factor for mortality. They also help to reduce post-operative complications such as infections and delays in healing, with appropriate active ingredients.
Dans une autre approche, il existe des compléments alimentaires dits « multivitamines » contenant un cocktail d’au moins dix vitamines et minéraux, généralement choisis parmi les vitamines A, B (B1, B2, B3, B5, B6, B8, B9, B12), C, D, E, K, le calcium, le chrome, le cuivre, le fer, l’iode, le potassium, le magnésium, le sélénium et le zinc. Ils peuvent de plus contenir des plantes à visée énergisante. Ils sont recommandés pour renforcer la vitalité, l’énergie, booster les défenses immunitaires. Ces compléments sont souvent consommés en péri-opératoire par des patients non dénutris, en automédication. Les chirurgiens et anesthésistes ne sont pas forcément informés de cette consommation par les patients. Ils présentent néanmoins l’inconvénient de ne pas être dénués d’effets secondaires et précisément dans cette période péri-opératoire au cours de laquelle le patient a reçu des traitements thérapeutiques, tels que par anticoagulants, anesthésiques, analgésiques, antibiotiques.In another approach, there are food supplements called "multivitamins" containing a cocktail of at least ten vitamins and minerals, generally chosen from vitamins A, B (B1, B2, B3, B5, B6, B8, B9, B12 ), C, D, E, K, calcium, chromium, copper, iron, iodine, potassium, magnesium, selenium and zinc. They can also contain energizing plants. They are recommended to strengthen vitality, energy, and boost immune defenses. These supplements are often consumed perioperatively by non-malnourished patients, as self-medication. Surgeons and anesthetists are not necessarily informed of this consumption by patients. They nevertheless have the disadvantage of not being devoid of side effects and precisely in this perioperative period during which the patient has received therapeutic treatments, such as anticoagulants, anesthetics, analgesics, antibiotics.
On sait en particulier que la supplémentation en vitamine E favorise les hémorragies. Il a en effet été mis en évidencein vitroetin vivoque la vitamine E a une action inhibitrice sur les protéines kinase C qui sont impliquées dans la prolifération et la différentiation cellulaire des plaquettes entraînant une inhibition de l’agrégation plaquettaire et des risques hémorragiques. On sait aussi que la supplémentation en vitamine A a des conséquences délétères sur l’évolution du cancer du poumon, ainsi que la supplémentation en sélénium sur l’évolution du cancer de la prostate. Des plantes peuvent interférer avec les médicaments administrés à un patient dans un cadre péri-opératoire tels que listés ci-dessus, et entraîner un accroissement ou au contraire une diminution de leurs effets. En plus de ces interférences nocives, on sait que certains nutriments peuvent augmenter les risques de troubles cardiovasculaires péri-opératoires tels que l’hypo- ou l’hyper-tension ou des arythmies.In particular, we know that vitamin E supplementation promotes bleeding. It has indeed been demonstrated in vitro and in vivo that vitamin E has an inhibitory action on protein kinase C which is involved in the proliferation and cellular differentiation of platelets leading to inhibition of platelet aggregation and bleeding risks. . We also know that vitamin A supplementation has deleterious consequences on the development of lung cancer, as well as selenium supplementation on the development of prostate cancer. Plants may interfere with medications administered to a patient in a perioperative setting as listed above, and cause an increase or decrease in their effects. In addition to these harmful interferences, it is known that certain nutrients can increase the risks of perioperative cardiovascular disorders such as hypo- or hyper-tension or arrhythmias.
Le recours a un complément alimentaire dans un contexte péri-opératoire en vue d’un rétablissement peut donc ne pas être inoffensif, il peut même se révéler dangereux.The use of a food supplement in a perioperative context with a view to recovery may therefore not be harmless, it may even prove dangerous.
L’invention apporte un complément alimentaire, qui permet de surmonter les inconvénients précités, tout en apportant les éléments nécessaires à une convalescence rapide et un retour « à la normale » des fonctions biologiques, en restaurant en particulier l’énergie, l’immunité et les fonctions cognitives du patient.The invention provides a food supplement, which makes it possible to overcome the aforementioned drawbacks, while providing the elements necessary for rapid convalescence and a return "to normal" of biological functions, in particular restoring energy, immunity and the patient's cognitive functions.
Selon l’invention, il a été découvert que cet objectif pouvait être atteint avec un complément alimentaire comprenant de la vitamine B1 (thiamine), de la vitamine B2 (riboflavine), de la vitamine B5 (acide panthoténique), de la vitamine B6, de la vitamine C (acide ascorbique), du zinc et du magnésium, mais étant essentiellement exempt, de préférence complètement exempt, des vitamines B3, B8, B9, B12, A, D, E et K, de polyphénols, d’alcaloïdes différents de la caféine, et de tout extrait végétal susceptible d’inhiber ou induire l’un quelconque des isoenzymes CYP1A2, CYP2C9, CYP2D6 et CYP3A4 du cytochrome P450 ou d’interagir avec l’agrégation plaquettaire.According to the invention, it was discovered that this objective could be achieved with a food supplement comprising vitamin B1 (thiamine), vitamin B2 (riboflavin), vitamin B5 (panthotenic acid), vitamin B6, vitamin C (ascorbic acid), zinc and magnesium, but being essentially free, preferably completely free, of vitamins B3, B8, B9, B12, A, D, E and K, polyphenols, different alkaloids caffeine, and any plant extract likely to inhibit or induce any of the cytochrome P450 isoenzymes CYP1A2, CYP2C9, CYP2D6 and CYP3A4 or to interact with platelet aggregation.
Un tel complément peut être ainsi consommé en auto-médication. Il est plus spécifiquement destiné aux personnes de plus de 15 ans et non recommandé pour les femmes enceintes ou allaitantes.Such a supplement can thus be consumed as self-medication. It is more specifically intended for people over 15 years old and not recommended for pregnant or breastfeeding women.
Avant d’aborder l’invention plus en détails, la définition de certains termes employés dans le présent texte est précisée.Before discussing the invention in more detail, the definition of certain terms used in this text is specified.
Par alcaloïdes, on comprend des molécules organiques hétérocycliques avec au moins un atome d’azote, à caractère alcalin, d'origine végétale, généralement contenues dans des compléments alimentaires en raison de leurs propriétés stimulantes.By alkaloids we understand heterocyclic organic molecules with at least one nitrogen atom, of alkaline nature, of plant origin, generally contained in food supplements due to their stimulating properties.
Le terme « polyphénols » inclut toute molécule organique d’origine végétale et constituée d’au moins un groupe phénolique, à savoir les acides phénoliques, les flavonoïdes, l’acide chlorogénique et les quinones, ainsi que leurs dérivés résultant d’une combinaison de ces derniers avec des sucres, et notamment leurs hétérosides éventuellement acylés, comme les tanins, les anthocyanes.The term "polyphenols" includes any organic molecule of plant origin and consisting of at least one phenolic group, namely phenolic acids, flavonoids, chlorogenic acid and quinones, as well as their derivatives resulting from a combination of the latter with sugars, and in particular their possibly acylated glycosides, such as tannins and anthocyanins.
Le cytochrome P450 est un système enzymatique qui regroupe plusieurs enzymes (CYP) qui interviennent dans le métabolisme hépatique des médicaments parmi lesquelles CYP1A2, CYP2C9, CYP2D6 et CYP3A4 sont les plus actives. Les végétaux susceptibles d’inhiber ou induire l’un des isoenzymes CYP1A2, CYP2C9, CYP2D6 et CYP3A4 du cytochrome P450, que ce soit par un effet inhibiteur ou stimulant, modifient ce métabolisme et en cela sont toxiques. Ils sont répertoriés et c’est une notion connue de l’homme du métier. A titre d’exemples, la valériane, la réglisse, le thé vert, le pamplemousse sont décrits comme étant des inhibiteurs du CYP3A4, et le millepertuis et le ginseng sont décrits comme majorant l’activité du CYP3A4. Un complément alimentaire de l’invention doit donc être dépourvu de ces végétaux ou de leurs extraits.Cytochrome P450 is an enzymatic system which brings together several enzymes (CYPs) which are involved in the hepatic metabolism of drugs, among which CYP1A2, CYP2C9, CYP2D6 and CYP3A4 are the most active. Plants likely to inhibit or induce one of the cytochrome P450 isoenzymes CYP1A2, CYP2C9, CYP2D6 and CYP3A4, whether through an inhibitory or stimulating effect, modify this metabolism and are therefore toxic. They are listed and this is a concept known to those skilled in the art. For example, valerian, licorice, green tea and grapefruit are described as being CYP3A4 inhibitors, and St. John's wort and ginseng are described as increasing CYP3A4 activity. A food supplement of the invention must therefore be free of these plants or their extracts.
Par extrait végétal susceptible d’interagir avec l’agrégation plaquettaire, on comprend tout extrait capable de ralentir ou inhiber l’agrégation plaquettaire en agissant directement ou indirectement sur un ou plusieurs des facteurs intervenant dans la cascade de la coagulation sanguine. A titre d’exemple, ledit extrait peut moduler la production d’oxyde d’azote (NO), notamment au niveau des endothéliums vasculaires, dont on sait qu’il inhibe les plaquettes en stimulant la production de la guanosine monophosphate (GMP) cyclique par activation d’une guanylate cyclase.By plant extract capable of interacting with platelet aggregation, we understand any extract capable of slowing down or inhibiting platelet aggregation by acting directly or indirectly on one or more of the factors involved in the blood coagulation cascade. For example, said extract can modulate the production of nitrogen oxide (NO), particularly at the level of vascular endothelia, which is known to inhibit platelets by stimulating the production of cyclic guanosine monophosphate (GMP). by activation of a guanylate cyclase.
Par l’expression « essentiellement exempt », on entend une présence tout au plus à l’état de traces, en une teneur n’excédant pas 0,0001% en masse par rapport à celle du complément. On préférera que cette présence soit si faible qu’elle est indétectable.By the expression “essentially free”, we mean a presence at most in trace amounts, in a content not exceeding 0.0001% by mass compared to that of the complement. We would prefer this presence to be so weak that it is undetectable.
Une dose de complément alimentaire dans le présent texte se rapporte à une prise de complémentaire alimentaire en une fois.A dose of food supplement in this text refers to taking a food supplement at one time.
L’invention est ci-après décrite plus en détails avec des mises en œuvre particulières, les caractéristiques déterminées pouvant être considérées seules ou en combinaison les unes avec les autres.The invention is described below in more detail with particular implementations, the determined characteristics being able to be considered alone or in combination with each other.
Selon une variante de l’invention, un complément alimentaire est essentiellement, de préférence complètement, exempt d’extraits de ginkgo biloba. En effet, ces extraits sont susceptibles d’interagir avec des médicaments, en particulier des médicaments contenant de l’aspirine dont ils potentialisent l’action et certains anti-coagulants.According to a variant of the invention, a food supplement is essentially, preferably completely, free of ginkgo biloba extracts. Indeed, these extracts are likely to interact with medications, in particular medications containing aspirin whose action they potentiate and certain anticoagulants.
Selon une autre variante de l’invention, un complément alimentaire est essentiellement, de préférence complètement, dépourvu de sélénium qui a des conséquences délétères dans certaines pathologies, comme le cancer de la prostate.According to another variant of the invention, a food supplement is essentially, preferably completely, devoid of selenium which has deleterious consequences in certain pathologies, such as prostate cancer.
Avantageusement, notamment en indication post-opératoire, un complément alimentaire de l’invention comprend de la caféine. En combinaison avec le magnésium, elle favorise l’émergence de la sédation et de l’anesthésie.Advantageously, particularly as a post-operative indication, a food supplement of the invention comprises caffeine. In combination with magnesium, it promotes the emergence of sedation and anesthesia.
Une formulation préférentielle d’un complément alimentaire de l’invention est ci-après détaillée ; il comprend, pour une dose, et selon une variante, il consiste, pour une dose, en :A preferred formulation of a food supplement of the invention is detailed below; it comprises, for one dose, and according to a variant, it consists, for one dose, of:
100 à 150 mg de magnésium100 to 150 mg of magnesium
80 à 150 mg de de la vitamine C,80 to 150 mg of vitamin C,
1 à 5 mg de vitamine B5,1 to 5 mg of vitamin B5,
1 à 2 mg de zinc,1 to 2 mg of zinc,
0,5 à 1 mg de vitamine B1,0.5 to 1 mg of vitamin B1,
0,5 à 1 mg de vitamine B2, et0.5 to 1 mg of vitamin B2, and
0,2 à 0,5 mg de vitamine B6.0.2 to 0.5 mg of vitamin B6.
Cette formulation peut être complétée par 20 à 50 mg de caféine.This formulation can be supplemented with 20 to 50 mg of caffeine.
Elle correspond à une dose journalière.It corresponds to a daily dose.
Un complément alimentaire de l’invention peut encore comprendre un ou des additifs et notamment un ou ceux choisis parmi les agents conservateurs, les colorants, les arômes, les agents de délitement, les liants, les diluants, les agents lubrifiants, les agents d'enrobage ou d'encapsulation, ceux-ci pouvant être présents en une teneur qui va de 3 à 15% (m/m) par rapport au complément.A food supplement of the invention may also comprise one or more additives and in particular one or those chosen from preservatives, colorings, flavorings, disintegration agents, binders, diluents, lubricating agents, coating or encapsulation, these may be present in a content ranging from 3 to 15% (m/m) relative to the complement.
Il peut être préparé et se présenter sous toute forme classique d’un complément alimentaire et notamment sous la forme de gélules, de capsules, de comprimés, de gommes à mâcher, de pastilles, de poudre libre ou de sirop.It can be prepared and presented in any classic form of a food supplement and in particular in the form of capsules, capsules, tablets, chewing gum, lozenges, loose powder or syrup.
L’invention concerne en outre l’utilisation d’un complément alimentaire tel que décrit précédemment dans une indication péri-opératoire non-thérapeutique, antérieure ou postérieure à une intervention chirurgicale.The invention further relates to the use of a food supplement as described above in a non-therapeutic perioperative indication, before or after a surgical intervention.
S’il peut manifester un intérêt particulier dans le traitement non-thérapeutique, antérieurement ou postérieurement à une intervention chirurgicale de patients devant subir ou ayant subi une intervention chirurgicale liée à une tumeur cancéreuse, comme le retrait d’une tumeur cancéreuse du poumon ou de la prostate, il a l’avantage de pouvoir être consommé par tout patient qu’il soit sain ou atteint d’addiction, comme un fumeur, ou d’une maladie indépendante de l’intervention chirurgicale, par exemple une maladie chronique comme l’hypertension. Ainsi, même en auto-médication, un complément alimentaire ne présente pas de risque, y compris dans un contexte péri-opératoire.If he may show a particular interest in the non-therapeutic treatment, before or after a surgical intervention of patients undergoing or having undergone a surgical intervention linked to a cancerous tumor, such as the removal of a cancerous tumor of the lung or the prostate, it has the advantage of being able to be consumed by any patient, whether healthy or suffering from addiction, such as a smoker, or an illness independent of the surgical intervention, for example a chronic illness such as hypertension. Thus, even when self-medicating, a food supplement does not present any risk, including in a perioperative context.
Claims (9)
- 100 à 150 mg de magnésium
- 80 à 150 mg de de la vitamine C,
- 1 à 5 mg de vitamine B5,
- 1 à 2 mg de zinc,
- 0,5 à 1 mg de vitamine B1,
- 0,5 à 1 mg de vitamine B2, et
- 0,2 à 0,5 mg de vitamine B6.Food supplement according to any one of the preceding claims, characterized in that it comprises, for one dose:
- 100 to 150 mg of magnesium
- 80 to 150 mg of vitamin C,
- 1 to 5 mg of vitamin B5,
- 1 to 2 mg of zinc,
- 0.5 to 1 mg of vitamin B1,
- 0.5 to 1 mg of vitamin B2, and
- 0.2 to 0.5 mg of vitamin B6.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2209995A FR3140243A1 (en) | 2022-09-30 | 2022-09-30 | Dietary supplement |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2209995A FR3140243A1 (en) | 2022-09-30 | 2022-09-30 | Dietary supplement |
FR2209995 | 2022-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
FR3140243A1 true FR3140243A1 (en) | 2024-04-05 |
Family
ID=84887478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR2209995A Pending FR3140243A1 (en) | 2022-09-30 | 2022-09-30 | Dietary supplement |
Country Status (1)
Country | Link |
---|---|
FR (1) | FR3140243A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011012008A (en) * | 2009-07-01 | 2011-01-20 | Otsuka Pharmaceut Factory Inc | Infusion preparation for peripheral intravenous administration |
US20190209507A1 (en) * | 2016-08-26 | 2019-07-11 | Atif Dabdoub | Dietary macro/micronutritional supplement for patients undergoing kidney dialysis |
US20200155589A1 (en) * | 2018-06-15 | 2020-05-21 | Gerald Haase | Composition For Enchanced Recovery After Surgery (ERAS) |
WO2021167562A1 (en) * | 2020-02-21 | 2021-08-26 | Montero Gida Sanayi Ve Ticaret Anonim Sirketi | Nutritional compositions for cancer patients undergoing chemotherapy and/or radiotherapy and/or pre-post surgery |
-
2022
- 2022-09-30 FR FR2209995A patent/FR3140243A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011012008A (en) * | 2009-07-01 | 2011-01-20 | Otsuka Pharmaceut Factory Inc | Infusion preparation for peripheral intravenous administration |
US20190209507A1 (en) * | 2016-08-26 | 2019-07-11 | Atif Dabdoub | Dietary macro/micronutritional supplement for patients undergoing kidney dialysis |
US20200155589A1 (en) * | 2018-06-15 | 2020-05-21 | Gerald Haase | Composition For Enchanced Recovery After Surgery (ERAS) |
WO2021167562A1 (en) * | 2020-02-21 | 2021-08-26 | Montero Gida Sanayi Ve Ticaret Anonim Sirketi | Nutritional compositions for cancer patients undergoing chemotherapy and/or radiotherapy and/or pre-post surgery |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Borghi et al. | Nutraceuticals with a clinically detectable blood pressure‐lowering effect: a review of available randomized clinical trials and their meta‐analyses | |
Cicero et al. | Nutraceuticals and blood pressure control: results from clinical trials and meta-analyses | |
Cicero et al. | Nutrients and nutraceuticals for the management of high normal blood pressure: an evidence-based consensus document | |
US6368640B1 (en) | Method and composition for improving sexual fitness | |
US6814958B1 (en) | Food compositions, compositions for oral cavity and medicinal compositions for preventing or treating periodontosis and method for preventing or treating periodontosis | |
US9192638B2 (en) | Preparation comprising amino acids and plants and its activity in the alcohol detoxification | |
JP5019875B2 (en) | Composition that promotes alcohol metabolism or improves fatigue by gluconeogenesis | |
TW202103574A (en) | Sports and nutritional supplement formulations | |
US11229600B2 (en) | Compositions and methods for selective GI tract delivery | |
US20120020947A1 (en) | Compositions and methods for increasing lean muscle mass after exercise | |
Houston | Treatment of hypertension with nutrition and nutraceutical supplements: Part 2 | |
Houston | Nutrition and nutraceutical supplements for the treatment of hypertension: Part III | |
FR3140243A1 (en) | Dietary supplement | |
JP2011504464A (en) | Novel blood pressure lowering composition | |
JP2007236308A (en) | Food composition | |
FR2888725A1 (en) | Food supplement containing rapeseed extract, green tea extract and zinc, used to treat or prevent androgenic alopecia, hyperseborrhea and acne | |
US7371415B1 (en) | Method and composition for improving sexual fitness | |
JP2023000008A (en) | oral composition | |
CN100566734C (en) | The Orally administered composition that is used for the treatment of cellulite | |
JP7418170B2 (en) | Oral composition | |
JP7436166B2 (en) | Menopausal symptom improvement agent | |
Nozawa et al. | Consumption of dried-bonito broth acutely increases peripheral blood flow in humans | |
US20240058411A1 (en) | Composition for treating and/or preventing a hangover | |
Berbari et al. | Secondary hypertension: infrequently considered aspects—illicit/recreational substances, herbal remedies, and drug-associated hypertension | |
JP5383549B2 (en) | NO production promoting composition and male function improving agent containing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 2 |
|
PLSC | Publication of the preliminary search report |
Effective date: 20240405 |